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PURPOSE. Pituitary adenylate cyclase activating polypeptide (PACAP) is neuroprotective in
neuronal injuries. Bilateral common carotid artery occlusion (BCCAO) causes chronic
hypoperfusion-induced degeneration in the rat retina, where we proved the retinoprotective
effect of intravitreal PACAP. Although this route of administration is a common clinical
practice in several diseases, easier routes are clinically important. Our aim was to investigate
the potential retinoprotective effects of PACAP eye drops in BCCAO-induced ischemic
retinopathy.
METHODS. After performing BCCAO in rats, the right eyes were treated with PACAP1-27 eye
drops (1 lg/drop, 2 3 1 drops/day for 5 days), containing different vehicles: saline, water for
injections, thiomersal or benzalkonium solution for ophthalmic use (SOCB). Histology and
immunohistochemistry were performed 2 weeks after surgery, while molecular analysis was
performed 24 hours after BCCAO. Passage of PACAP1-27 through the ocular layers was tested
with radioactive PACAP-SOCB in mice.
RESULTS. Bilateral common carotid artery occlusion led to a severe degeneration of all retinal
layers. Solution for ophthalmic use was the most effective vehicle for delivering PACAP
(PACAP-SOCB), significantly ameliorating BCCAO-induced damage. The massive upregulation
of GFAP was not observed in retinas treated with PACAP-SOCB eye drops. PACAP-SOCB
treatment also increased activation of the protective Akt and ERK1/2 in hypoperfused retinas.
The cytokine profile showing upregulation in different cytokines was attenuated by PACAP-
SOCB. Radioactive PACAP reached the retina when delivered in SOCB-containing eye drops.
CONCLUSIONS. PACAP1-27, delivered in the SOCB vehicle as eye drops, was retinoprotective in
ischemic retinopathy, providing the basis for future therapeutic administration.
Keywords: eye drops, ischemia, retina, neuropeptide
Pituitary adenylate cyclase activating polypeptide (PACAP) isa neuropeptide with diverse biological actions. It elicits
these actions by binding the G-protein-coupled receptors, PAC1
and VPAC1/2, which also bind vasoactive intestinal polypeptide
(VIP).1 Soon after the discovery of PACAP it became evident
that the peptide has strong neuroprotective effects, in several
in vitro and in vivo models.2–6 The first in vivo proof of its
neuroprotective action came from studies of global cerebral
ischemia.7 Subsequent studies confirmed the efficacy of PACAP
in cerebral ischemic conditions and also in ischemic lesions of
other organs, including kidney, intestine, and heart.8–10
In the retina, ischemic injury can be induced by ligating
both carotid arteries transiently or permanently (bilateral
carotid artery occlusion; BCCAO), leading to ischemia/reperfu-
sion injury or chronic retinal hypoperfusion, respectively,
methods that mimic several hallmarks of chronic retinal
degeneration.11 PACAP is protective in both types of ischemic
retinal lesions.5,12,13 Earlier we showed that PACAP1-38
ameliorates the reduction in thickness of different retinal layers
as well as the loss of cells in the ganglion cell layer (GCL) in
BCCAO-induced injury.12,14 PACAP1-38 and 1-27 exert a similar
degree of protection, while other fragments (PACAP6-38,
PACAP6-27) and related peptides are either noneffective or
deteriorate the injury.15,16 We also found that PACAP counter-
acts the ischemia-induced cytokine changes and promotes
antiapoptotic pathways.17
Altogether, these results provide strong evidence that PACAP
has potential therapeutic value in ischemic retinopathy.
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However, a major drawback of PACAP-induced retinal therapy
is that in all these studies PACAP was given intravitreally.
Although this route of administration is a common clinical
practice in several diseases, like age-related macular degener-
ation (AMD) and diabetic retinopathy,18 easier administration
routes would be very important from the clinical point-of-view.
Topical administration (eye drops) provides a suitable nonin-
vasive method for treating ophthalmic diseases.19 PACAP eye
drops have been shown to have topical effects in the
cornea,20,21 but it is not known whether PACAP would
penetrate the ocular barriers, reaching the retina. Therefore,
the aim of the present study was to investigate the
retinoprotective efficacy of PACAP given as eye drops in
ischemic retinopathy.
MATERIALS AND METHODS
Surgery and PACAP-SOCB Treatment
In a preliminary experiment aimed to reveal the best vehicle
for delivery of PACAP in eye drops, PACAP1-27 was dissolved in
the following vehicles: saline, water for injections (aqua ad
iniectabila), thiomersal solution for ophthalmic use (solvens
viscosa pro oculoguttis cum thiomersalo), benzalkonium
solution for ophthalmic use (solutio ophthalmica cum benzal-
konio; SOCB). As SOCB was the most effective vehicle based
on the histologic analysis, it was used in the subsequent
experiments. Therefore, in the following sections, PACAP
treatment indicated treatment with PACAP1-27 eye drops in
SOCB in all cases.
Adult male Wistar rats (n ¼ 83: n ¼ 28 for histologic
analysis, n ¼ 7 for immunhistochemical analysis, n ¼ 19 for
immunoblot analysis, n¼ 28 for cytokine array) weighing 250
to 300 g were subjected to BCCAO. The animals were bred
and kept in the Animal Facility of the Medical School
University of Pecs (Pecs, Hungary). They were housed in
individual cages, fed and watered ad libitum, under light/dark
cycles of 12/12 hour. All procedures were in accordance with
the ethical guidelines approved by the University of Pecs
(BA02/2000-31/2011) and directives of the National Ethical
Council for Animal Research, the European Communities
Council (86/609/EEC), and ARVO Statement for the Use of
Animals in Ophthalmic and Vision Research. Under isoflurane
anesthesia, common carotid arteries were exposed bilaterally
through a midline incision and ligated with a 3-0 filament.
Immediately following the BCCAO operation, the right eye
was treated with PACAP1-27 eye drops (1 lg/drop). As in our
past studies, PACAP1-27 was synthesized at the University of
Szeged (Szeged, Hungary) as described in details elsewhere.22
The left eye, serving as a control, was treated only with
vehicle. A group of animals underwent anesthesia and all
steps of the surgical procedure except ligation of the carotid
arteries (midline incision of the neck and wound closure,
sham group). Rats were treated for 5 consecutive days, twice
a day with one drop.
Histologic Analysis of PACAP1-27
Rats (n ¼ 7 sham, n ¼ 7 sham þ PACAP-SOCB and n ¼ 21
BCCAO, n ¼ 21 BCCAO þ PACAP-SOCB retinas) were killed
with an overdose of anesthetic 2 weeks after BCCAO and eyes
were processed for histologic analysis. Histologic analysis was
performed as described previously.14 Briefly, eyes were
removed and retinas were dissected in PBS, fixed in 4%
paraformaldehyde dissolved in 0.1M phosphate buffer (PB),
embedded in Durcupan ACM resin, and 2-lm thick sections
were stained with toluidine blue (Sigma, Budapest, Hungary).
Four tissue blocks from at least four animals were prepared and
central retinal areas within 1 mm from the optic nerve were
used (n¼5 measurements from one tissue block). Photographs
were taken with a digital CCD camera (Nikon) using the Spot
program (Spot Imaging, Sterling Heights, MI, USA). The
following parameters were measured: cross-section from the
outer limiting membrane (OLM) to the inner limiting mem-
brane (ILM), and width of all retinal layers (outer nuclear layer
[ONL], outer plexiform layer [OPL], inner nuclear layer [INL],
inner plexiform layer [IPL]). The number of cells in the
ganglion cell layer (GCL) was also measured. Results are
presented as mean 6 SEM.
Radioactive Labeling of PACAP1-27
PACAP1-27 was labeled with 125I using the lactoperoxidase
method.23 Briefly, 10 lg of PACAP1-27 (dissolved in 0.25M
chloride-free PB) was mixed with 30 lL of 0.4M Na acetate (pH
5.6), 10 lL of lactoperoxidase (10 lg/mL dissolved in 0.1M Na
acetate pH 5.6), and 1 mCi of 125I. The reaction was started by
adding 10 lL 30% H2O2 solution (prepared by adding 2 lL
H2O2 in 30 mL dI H2O). Ten minutes later, an additional 10 lL
of the 30% H2O2 solution was added and the reaction allowed
to progress 10 minutes more. At the end of this second 10-
minutes incubation, the reaction solution was purified with
HPLC (Shimadzu USA Manufacturing, Inc., Columbia, MD, USA)
using a C18 column (P.J. Cobert Associates, Inc., St. Louis, MO,
USA).
PACAP1-27 Eye Drop Preparation
The PACAP1-27 fraction collected from the HPLC was
evaporated overnight in a fume hood using constant air flow
to evaporate off the 0.1% trifluoroacetic acid in methanol
solution that the fraction was collected in. The dried fraction
was resuspended in 1% BSA Lactated Ringers’ solution (Baxter
Healthcare, Deerfield, IL, USA) and an acid precipitation was
completed to assess the purity of the PACAP1-27 fraction. The
acid precipitation was completed with 15% trichloroacetic
acid. The percent of radioactivity precipitated was calculated
using the following formula:
1003 ðCPM pelletÞ=ðCPM pellet þ CPM supernatantÞ½ 
Only fractions that showed greater than 90% activity in the
precipitate were used in the experiment. A 1 3 106 cpm
solution was prepared in a 10-lL volume of benzalkonium-
chloride. A 10-lL drop was placed on each eye delivering 13
106 cpm per eye.
Tissue Collection
Male CD-1 mice were anesthetized with urethane and
administered PACAP1-27 as an eye drop (1 3 106 cpm/eye
in benzalkonium-chloride). At various time-points, blood was
collected from the carotid artery, and the eyes and whole
brain removed. The time-points used in this study were 5, 30,
60, and 120 minutes. Mice (n¼ 3–6) were used at each time-
point. The collected whole blood was allowed to clot at room
temperature, centrifuged at 5400 g for 10 minutes at 48C, and
50 lL of resulting serum was removed for use. The whole
brain was collected and the eye dissected into the cornea,
retina, and vitreous humor. The level of radioactivity in each
of the regions and the serum was measured in a Wizard2
Automatic Gamma Counter (PerkinElmer, Waltham, MA,
USA). The percentage of injected dose present in a milliliter
of serum (%Inj/mL) and the percentage of the injected dose
taken up per gram of tissue (%Inj/g) was calculated as
previously described.24,25
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Measurement of Glial Fibrillary Acidic Protein
(GFAP) Activity in the Mu¨ller Glial Cells
For immunohistochemical analysis, 2 weeks after the induction
of ischemia, animals (n¼ 2 sham, n¼ 2 sham þ PACAP-SOCB,
and n¼ 5 BCCAO; n¼ 5 BCCAO þ PACAP-SOCB retinas) were
killed with an overdose of anesthetic (120 mg/kg pentobarbi-
tal, Nembutal; Sanofi-Phylaxia, Budapest, Hungary), the eyes
were immediately dissected in ice-cold PBS and fixed in 4%
paraformaldehyde dissolved in 0.1M PB (pH 7.4) for 4 hours at
room temperature, similarly to earlier descriptions.14 Briefly,
tissues were washed in 0.1M PB (6 3 10 minutes) and
cryoprotected in 10% and 20% sucrose for 1 hour, followed by
30% sucrose in PBS overnight at 48C. For cryostat sectioning,
retinas were embedded in tissue freezing medium (Cryomatrix,
Thermo Scientific, Waltham, MA, USA), and cut in a cryostat
(Leica, Nussloch, Germany) at 10 to 12 lm. Central retinal
areas within 2 mm from the optic nerve head were used for
immunocytochemical analysis. Sections were mounted on
chrome–alum–gelatin coated slides and stored at 208C until
use. Retinal sections were rinsed in PBS, permeabilized by
incubation for 6 3 5 minutes in 0.1% Triton X-100 (Sigma) in
PBS and incubated with 3% normal donkey serum and 0.1% Na-
azide in PBS for 1 hour to minimize nonspecific labeling.
Sections were incubated with the primary polyclonal antibody
overnight at 48C. We used the anti-GFAP antibody (rabbit anti-
GFAP 1:1000; Sigma). The antibody was included in 1% donkey
serum (Sigma). After 6 washes in PBS, sections were incubated
for 2 hours at room temperature in the dark with the
corresponding secondary fluorescent anti-rabbit antibody
Alexa Fluor 488 (donkey anti-rabbit, 1:200; Life Technologies,
Budapest, Hungary). Sections were then washed in PBS and
propidium iodide (PI; 1:500; Sigma) was used to detect the
nuclear components. After 3 washes in PBS, sections were
coverslipped using Fluoroshield (Sigma). For control experi-
ments, primary antibodies were omitted, resulting in no
specific staining. Digital photographs were taken with a Nikon
Eclipse Ci fluorescence microscope (Nikon, Melville, NY, USA).
Photographs were further processed with the Adobe Photo-
shop CS6 program (Adobe Systems, Inc., San Jose, CA, USA).
Images were adjusted for contrast only; they were aligned,
arranged, and labeled by using the functions of the above
program. An examiner blinded to the experimental treatment
evaluated the images collected.
Immunoblot Analysis
For Western blot experiments, a separate group of retinas was
removed 2 weeks (n¼3 sham, n¼3 shamþPACAP-SOCB, or n
¼9 BCCAO, n¼9 BCCAOþPACAP-SOCB retinas) and 24 hours
(n¼4 sham, n¼4 shamþPACAP-SOCB, and n¼4 BCCAO, n¼
4 BCCAO þ PACAP-SOCB retinas) after BCCAO. Samples were
processed for Western blot analysis as described earlier.17
Membranes were probed overnight at 48C with anti-Akt-1
Ser473 (1:1000; R&D Systems, Budapest, Hungary), phospho-
specific anti-ERK1/2 Thr202/Tyr204 (1:1000; Cell Signaling
Technology, Danvers, MA, USA), total-Akt (tAkt) antibody was
used as internal control for phospho-Akt (pAkt), actin antibody
was used as control for phospho-ERK (pERK) 1/2. Membranes
were washed six times for 5 minutes in TRIS-buffered saline
(pH 7.5) containing 0.2% Tween prior to the addition of goat
anti-rabbit or anti-mouse horseradish-peroxidase conjugated
secondary antibody (1:3000; BioRad, Budapest, Hungary). The
antibody–antigen complexes were visualized by means of
enhanced chemiluminescence. After the scanning step, results
were quantified using the ImageJ software (http://imagej.nih.
gov/ij/; provided in the public domain by the National
Institutes of Health, Bethesda, MD, USA). The retina from each
rat was analyzed twice in two separate experiments. Pixel
volumes of the spot were normalized to the internal controls.
Data are represented by pixel density in arbitrary units.
Cytokine Array
For semiquantitative cytokine array, retinas (n¼ 11 sham, n¼
11 shamþ PACAP-SOCB, and n¼ 17 BCCAO, n¼ 17 BCCAOþ
PACAP-SOCB retinas) were removed after 24 hours of BCCAO
operation and homogenized in PBS with protease inhibitors.
Samples were pooled in three replicates (n¼ 3 per replicate).
Triton X-100 was added to a final concentration of 1%.
Samples were stored at 808C prior to use. Cytokine array
from tissue homogenates was performed using Rat Cytokine
Array Panel A Array kit from R&D Systems (Biomedica,
Budapest, Hungary). After blocking the array membranes for
1 hour and adding the reconstituted Detection Antibody
Cocktail for another 1 hour at room temperature, the
membranes were incubated with 1.5 mL of tissue homoge-
nates at 28C to 88C overnight on a rocking platform. After
washing with buffer three times and addition of horseradish
peroxidase-conjugated streptavidin to each membrane we
exposed them to a chemiluminescent detection reagent
(Amersham Biosciences, Budapest, Hungary) then to an X-
ray film cassette.17 The developed films were scanned, and
the pixel volumes of the spot were determined by using
ImageJ Protein Array Analyzer. Pixel volumes of the spot of
interest were normalized to the control (sham retinas).26 The
array was repeated four times.
Statistical Analysis
Statistical comparisons were made using the 2-way ANOVA
followed by Fischer’s post hoc analysis.
RESULTS
Retina Morphology and Morphometry
Bilateral common carotid artery occlusion resulted in severely
reduced thickness of retinal layers 2 weeks after ligation,
compared with sham animals (Figs. 1A, 1B). PACAP1-27 alone
in sham animals did not result in alteration of any retinal layer
(Figs. 1A, 1B). PACAP1-27 dissolved in solutio ophthalmica cum
benzalkonio (PACAP-SOCB) led to significant protection in the
retina in BCCAO. The BCCAO retinas treated with PACAP-
SOCB had a more preserved structure compared with vehicle-
treated retinas (Fig. 1A). Outer limiting membrane–ILM
distance was reduced by 50.7% (P < 0.0001) in ischemic
retinas compared with sham controls, but was reduced only by
36.1% (P < 0.0001) in the eyes treated with PACAP-SOCB.
Similar protection could be observed in the OPL (BCCAO:
54.2%, BCCAO þ PACAP1-27: 47.9%; P < 0.005), INL (BCCAO:
46.5%, BCCAO þ PACAP1-27: 30.7%; P < 0.0001), and IPL
(BCCAO: 61.4%, BCCAO þ PACAP1-27: 38.3%; P < 0.0001),
while no protection could be seen in the ONL (BCCAO: 35.3%,
BCCAO þ PACAP1-27: 36.3%) (Fig. 1B). The number of cells in
the GCL was significantly decreased in ischemic retinas by
53.2% and was significantly increased by PACAP-SOCB
(reduced only by 28.1%; Fig. 1C). Based on the findings, SOCB
was the most effective vehicle for PACAP to exert neuropro-
tective effect in the retina; therefore, we used this solution for
further experiments.
PACAP1-27 Uptake After Ocular Administration
Radioactively labeled PACAP1-27 (I-PACAP) was administered
ocularly in SOCB to male CD-1 mice for a period ranging from 5
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FIGURE 1. (A) Light microphotographs of retinal sections. Retinal tissue from BCCAO (n¼21) (c) showed severe degeneration compared with sham
(n¼7) (a) and shamþPACAP-SOCB retinas (n¼7) (b). The retinal layers of BCCAO rats following treatment with eye drops containing PACAP-SOCB
(n¼ 21) (d) showed only mild degeneration. (Scale bar: 50 lm). (B, C) Quantification of retinal layers in sham (n¼ 7 sham, n¼ 7 sham þ PACAP-
SOCB) and BCCAO (n¼ 21 BCCAO, n¼21 BCCAOþPACAP-SOCB) animals: the right eye was treated with PACAP-SOCB eye drops (PACAP1-27), the
left eye served as controls receiving only SOCB. Comparison of retinal layers (B) and the number of cells/100 lm GCL length (C) in sham animals, rats
with BCCAO and those receiving PACAP-SOCB (PACAP1-27) eye drops treatment after carotid occlusion. Morphometric analysis showed that
treatment with eye drops improved the structure of all the retinal layers (except ONL). Statistical significance (***P < 0.001 versus sham retinas, $$$P
< 0.001 versus shamþPACAP1-27 retinas, †††P < 0.001 versus BCCAO retinas) was calculated by 2-way ANOVA followed by Fischer’s post hoc test.
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to 120 minutes. Transport of I-PACAP occurred rapidly as
detection of radioactivity was present in the eye, the brain, and
the serum 5 minutes post application. I-PACAP showed
transport across the cornea (Fig. 2A), peaking 60 minutes
after application. The vitreous humor showed a similar profile
to the cornea (Fig. 2C). In the retina (Fig. 2B), I-PACAP uptake
increased with time, plateauing at 60 minutes. I-PACAP was
transported rapidly to the whole brain (Fig. 2D) before starting
to decline after 30 minutes. By 120 minutes post application,
the I-PACAP signal was barely detectable in the brain.
Appearance of I-PACAP in the blood stream after ocular
administration was delayed (Fig. 2E).
Analysis of Mu¨ller Glial Cells
Glial fibrillary acidic protein filaments are intermediate
filaments expressed mainly by astrocytes and ependymal cells
in the central nervous system. In the retina, they are normally
present in the inner part of the Mu¨ller glial cells and their
endfeet forming the ILM (Figs. 3A, 3B).27 Glial fibrillary acidic
protein was markedly upregulated following BCCAO with an
altered distribution pattern: immunopositive signal was ob-
served in the entire cell from the OLM to ILM (Fig. 3C). PACAP-
SOCB eye drops appeared to ameliorate GFAP upregulation to
some extent (Fig. 3D).
FIGURE 2. Distribution of radioactively labeled PACAP1-27 after ocular administration. Appearance of 125I-labeled PACAP1-27 delivered to the
cornea in SOCB (A), retina (B), vitreous humor (C), whole brain (D), and serum (E) at 5, 30, 60, and 120 minutes.
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Phosphorylation of Akt and ERK1/2 After PACAP
Treatment
No changes were detected between groups in retinas removed
2 weeks after BCCAO, however, marked alterations were seen
in retinas 24 hours after the induction of ischemia. Ischemia
itself caused a decrease in the expression of pAkt, which was
not only reversed by PACAP-SOCB, but a robust increase could
be observed (Figs. 4A, 4B). PACAP-SOCB treatment alone led to
a slight decrease of pERK1/2 compared with the sham group.
Ischemia induced a strong phosphorylation of ERK1/2
compared with sham retinas. This was further increased by
PACAP-SOCB (data not shown).
FIGURE 3. Representative vertical retinal sections stained by GFAP antibody showing the effect of BCCAO (n¼ 5 BCCAO, n¼ 5 BCCAO þ PACAP-
SOCB) compared with sham (n¼ 2 sham, n¼ 2 shamþPACAP-SOCB) retinas. Propidium iodide was used to detect the nuclear components. In the
sham (A) and sham þ PACAP-SOCB (B) retina preparations GFAP-immunoreactivity was restricted to the inner part and internal endfeet of Mu¨ller
cells. Retinal degeneration caused by BCCAO (C) showed strong upregulation of immunoreactivity. After PACAP-SOCB treatment (D)
immunopositivity was reduced. Scale bar: 50 lm.
FIGURE 4. Representative Western blots showing activation (phosphorylation) of Akt (A) in sham (n¼4), shamþPACAP-SOCB (n¼4), BCCAO (n¼
4), and BCCAOþPACAP-SOCB (n¼4) retinas. tAkt was used as internal control for pAkt. Statistical analysis of Western blot results for pAkt (B). Data
are given as mean 6 SEM. $$$P < 0.001 vs. sham þ PACAP-SOCB animals, †††P <0.001 versus BCCAO animals. Statistical significance was
calculated by 2-way ANOVA followed by Fischer’s post hoc test.
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Effect of PACAP-SOCB Eye Drops on Ischemia-
Induced Changes in Cytokine Expression
Cytokine expression was tested using a cytokine array (Figs.
5A, 5B). Expression of several cytokines increased after
ischemia, including chemoattractant proteins, chemokines of
the cytokine-induced neutrophil chemoattractant (CINC), and
macrophage inflammatory protein (MIP) families: CINC-1 and
MIP-3a. The activation of the thymus chemokine, tissue
inhibitor of metalloproteinase (TIMP-1), and VEGF was also
increased in the retinas that underwent BCCAO. PACAP-SOCB
treatment attenuated activation of all the above mentioned
cytokines (Fig. 5C). Expression of other cytokines analyzed by
the array did not show any marked changes (Figs. 5A, 5B).
Although several other cytokines showed slight alterations,
only those are displayed in graphs and discussed, where we
detected more than 20% change in the normalized data
compared with sham group.
DISCUSSION
In the present study, we showed that PACAP administration
delivered in the vehicle SOCB in form of eye drops is protective
in ischemic retinal lesion. Thus, these data not only confirm
the retinoprotective effects of PACAP in ischemic retinopathy,
but prove that PACAP, in an appropriate vehicle, can cross the
ocular barriers and reach the retina in a concentration
sufficient to stimulate the protective pathways leading to
reduced retinal damage.
One major disadvantage of in vivo PACAP treatments is the
poor bioavailability of the natural peptide due to its fast
cleavage by the dipeptidyl-peptidase (DPPIV) enzyme.1 Its half-
life in the serum is a few minutes only. Although PACAP crosses
the blood–brain barrier,28 the passage through the blood–
retina barrier has not been investigated. These properties can
explain why little or no retinal protective effect was observed
in a monosodium glutamate-induced excitotoxic retinal injury
model in newborn rats when PACAP was administered
systemically29 compared with local, intravitreal treatment.
Despite its rapid metabolism, PACAP has several advantages
that may be responsible for its widespread effects. For
example, the peptide shows high conformational stability
and its binding to lipid membranes is very stable, preventing
enzymatic degradation.30,31 Furthermore, binding to its recep-
tor induces long-term effects despite of the short half-life.32
PACAP has systemic effects when given intravenously or
intraperitoneally, such as a decrease in blood pressure, facial
flushing, migraine-like attacks in migraineurs, and hormonal
changes.33–36 Given these side effects and the fact that as far as
ocular diseases are concerned, the first choice of treatment is
topical application of drops or ointments, we aimed at
investigating whether topical PACAP administration would be
beneficial in a model of chronic retinal hypoperfusion. The
morphologic results of the present study showed that PACAP,
dissolved in SOCB, significantly ameliorated the BCCAO-
induced retinal damage, indicating that applying the appropri-
ate vehicle, PACAP can reach the retina from the ocular
surface. Indeed, using radioactive labeling, we provided
evidence that PACAP passes through the cornea, vitreous body
to the retina. In light of the above mentioned side effects, an
important finding of our study is that very little of the PACAP
administered in SOCB as eye drops reached the systemic
circulation or the brain. Specifically, the concentration of
PACAP in the blood was 0.5% and in brain was 0.1% of the
retina.
In addition to the usual intravenous or intraperitoneal
routes, several alternative routes of PACAP administration have
been applied in various experimental paradigms. Intranasal
administration is suggested for treatment of neurodegenerative
diseases.23,37 Topical application to skin was used to achieve
dermal vasodilation,38 while buccal delivery for treatment of
type 2 diabetes.39 Topical ocular application of PACAP has
already been used to test local, corneal effects of the peptide. It
FIGURE 5. Representative blot from the cytokine array measurements (A), where dots show cytokine expression detected by the array. The panels
show arrays from sham (n¼ 11), and sham þ PACAP-SOCB (n¼ 11), BCCAO (n¼ 17), and BCCAO þ PACAP-SOCB (n¼ 17) retinas. The table (B)
indicates the examined factors in each box, highlighting the changes observed after PACAP-SOCB treatment. Image analysis of cytokines (C)
showing more than 20% change after treatments compared with the sham group, analyzed by the semiquantitative cytokine array. The different
arrays were normalized to the sham controls, shown at baseline (100%). The bar charts show the relative changes in protein expressions based on
four independent measurements given in percentage (%).
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has been found that PACAP, given in eye drops, enhances
corneal wound recovery,20,40,41 stimulates lacrimal secre-
tion,40,41 and accelerates nerve regeneration.21 However, the
effects of topical PACAP on the retina have never been
investigated. Some other growth factors have already been
used as potential topical treatments, such as nerve growth
factor (NGF). For NGF, the best proven effects of corneal
administration are for corneal disorders, but NGF eye drops
reaches the retina and protective effects have been suggest-
ed.42,43 The pharmacokinetics of topical NGF treatment seems
different from that of PACAP: while NGF reaches its peak in the
retina 6 hours after treatment, we found that PACAP reaches its
maximum level in the retina 1 hour after administration. The
reason for this difference may relate to the molecular size, as
PACAP is a short neuropeptide in contrast to the high
molecular weight NGF protein.
Our present study also showed that PACAP exerts its
retinoprotective effects by similarly complex protective mech-
anisms as previously shown in intravitreal treatments. It has
antiapoptotic/antioxidant effects and promotes an anti-inflam-
matory status.44–47 We have previously shown that PACAP,
binding to its receptors present in the retina, stimulates
antiapoptotic, whereas inhibits proapoptotic pathways,17,44,45,48
including the pathways studied here: ERK1/2 and Akt. PACAP
not only has strong antiapoptotic properties, but also has anti-
inflammatory and antioxidant actions. In the retina, we have
previously described that PACAP shifts the injury-induced
inflammatory cytokine/chemokine profile toward an anti-
inflammatory profile17 in a very similar manner to our present
findings, where the BCCAO-induced increase of the cytokines
CINC-1, MIP-3a, thymus chemokine, TIMP-1, and VEGF was
attenuated by PACAP treatment. Glial cell activation is a
pathologic sign typically present in lesions, including retinal
ischemia. Here, we showed that Mu¨ller glial cell activation was
markedly increased after induction of ischemia, whereas ocular
PACAP-SOCB attenuated it, similarly to our earlier descriptions
in ischemic and diabetic retinal lesions.12,49–51 Wada and co-
workers47 have demonstrated that PACAP influences another
glial cell in the retina: they showed that the neuropeptide
attenuates N-methyl-D-aspartate (NMDA)-induced retinal damage
in association with modulation of the microglia/macrophage
status into an acquired deactivation subtype.47
In summary, we found that PACAP dissolved in SOCB and
delivered as eye drops exerted retinoprotective effects and
deserves further investigation in order to exploit its therapeu-
tic potential in retinal degenerations in an easy-to-use form of
application.
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